Alterity Therapeutics (ASX: ATH) Share Price Drops: Here’s Why

Sonal Goyal

20 October 2026 03:07 PM AEDT

Alterity Therapeutics (ASX: ATH) Share Price Drops: Here’s Why

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key highlights

Alterity Therapeutics (ASX:ATH) shares fell 17.19% to $0.265 during the Trading session on 20 October 2026.
On 19 October 2026 the company said its chief executive will take part in a fireside chat at the Craig-Hallum Virtual Biotech Catalyst Conference.
The session is on Thursday, 22 October 2026 at 2:30 p.m. Eastern Time in the United States.

Shares of Alterity Therapeutics Limited (ASX:ATH) fell 17.19% to $0.265 during the trading session on 20 October 2026. Separately, on 19 October 2026, the company announced that its chief executive officer will participate in a fireside chat at the Craig-Hallum Virtual Biotech Catalyst Conference. The share price move and the announcement occurred on different dates and are not linked in this article.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical-stage biotechnology company that is also listed on the Nasdaq under the ticker ATHE. It is based in Melbourne, Australia, and San Francisco, California. The company says it is focused on developing disease-modifying therapies for Parkinson’s disease and related disorders.

Its lead asset, ATH434, is being developed for multiple system atrophy (MSA), a rare and rapidly progressive neurodegenerative disease for which the company states there is no approved treatment. Alterity also operates a drug discovery platform that generates patentable compounds aimed at neurological diseases.

Conference participation details

The fireside chat will take place as part of the Craig-Hallum Virtual Biotech Catalyst Conference on Thursday, 22 October 2026 at 2:30 p.m. Eastern Time. The company chief executive will participate in the session. A link to an archived webcast will be made available after the event on the Events and Presentations page in the Investors section of the Alterity website.

The announcement is a notice of participation. It does not report new clinical data, regulatory decisions, financial results or changes to the development timetable.

ATH434 clinical background

The company’s description in the notice says ATH434 demonstrated clinically meaningful efficacy in a randomised, double-blind, placebo-controlled Phase 2 trial in participants with MSA, and that it also reported positive data in an open-label Phase 2 trial in participants with advanced MSA.

Alterity states that it is preparing to initiate a Phase 3 pivotal trial in MSA. The notice does not give a start date for that trial, a funding plan or details of regulatory discussions.

Sector backdrop

Biotechnology companies developing treatments for neurodegenerative diseases operate in an area where Clinical Trials are long, expensive and have historically had high failure rates. Rare disease programs may qualify for regulatory incentives in some jurisdictions, but approval still depends on trial outcomes.

Investor conferences are a common way for small biotechnology companies to present to institutions, particularly those with a US dual listing.

Risks shareholders should weigh

The company has not yet started its Phase 3 pivotal trial, and results from earlier trials do not guarantee similar outcomes in later stages. A Phase 3 program will require substantial funding, and the notice does not describe how it will be financed.

Clinical-stage companies typically have no product Revenue and rely on Capital raisings, which can dilute existing shareholders. Regulatory outcomes are uncertain. At $0.265, the 17.19% fall on 20 October 2026 illustrates the Volatility that can affect clinical-stage biotechnology shares.

What’s next

The fireside chat is scheduled for 22 October 2026 at 2:30 p.m. Eastern Time, with an archived webcast to follow on the company website. The company continues to prepare for the Phase 3 trial in MSA.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.